Heart drug developer Kardigan targets $1.4 billion valuation in US IPO - Reuters

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOd3FqaXptWW5rQTg3MEVQNXJiVGM1aDJ6aGgtNHBqU29nM0Z1UkNJUnF2LXNMSmRqRkMtWEZ6RHNzeHJUMWtVSUMyMGVCZDBFN2UtRVp2c2V3Y2NGSWdxNzA2eDhyVk1lRDBWYzNaMVdscjdjLTRwQTJTNkdPUlZHVVdsNjBxVDIwR3ljSTNLc293REFsNUI3bm5aZWs0ajRPTGFlSm5hWkRWMlFPS3RxaU1WcUpSUUplRk4xV01wd0w2TEJDcXhMd0VYMWdwQkNGdTBB?oc=5" target="_blank">Heart drug developer Kardigan targets $1.4 billion valuation in US IPO</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Clinical-stage biotech Kardigan aims for a valuation of up to $1.4 billion in its U.S. IPO, seeking to raise up to $373.3 million by offering 23.3 million shares priced between $14 and $16 each.

Kardigan has filed for a Nasdaq IPO, offering 23,333,334 shares at a price range of $14 to $16 per share.

Kardigan aims for a valuation of up to $1.4 billion in its U.S. IPO, planning to raise up to $373.3 million by selling 23.3 million shares at a price range of $14 to $16 per share.

Kardigan, Inc has filed for a proposed Nasdaq IPO under the ticker 'KARD', aiming to develop precision medicines for cardiovascular diseases.

Kardigan filed for an initial public offering in the U.S. to fund the development of precision medicines for cardiovascular diseases.